Guangshengtang announced that in the first half of 2026, it achieved operating income of 209 million yuan, a year-on-year decrease of 5.13%; a net loss attributable to shareholders of listed companies was 666.881 million yuan, a net loss of 708.378 million yuan after deducting non-recurring profit and loss. Basic earnings per share - 0.4187 yuan, weighted average return on net assets - 20.40%. Net assets attributable to shareholders of listed companies at the end of the reporting period were $1,339 million, down 4.40% from the end of the previous year. During the reporting period, a major national science and technology project for hepatitis B treatment involving Guangsheng Zhonglin, the innovative pharmaceutical subsidiary of the company, was approved; the phase III clinical trial of the innovative hepatitis B drug Nericovir GST-HG141 completed the enrollment of all 578 subjects; the issuance of A-shares to specific targets was completed, and the actual net capital raised was 710 million yuan.

Guangshengtang announced that in the first half of 2026, it achieved operating income of 209 million yuan, a year-on-year decrease of 5.13%; a net loss attributable to shareholders of listed companies was 666.881 million yuan, a net loss of 708.378 million yuan after deducting non-recurring profit and loss. Basic earnings per share - 0.4187 yuan, weighted average return on net assets - 20.40%. Net assets attributable to shareholders of listed companies at the end of the reporting period were $1,339 million, down 4.40% from the end of the previous year. During the reporting period, a major national science and technology project for hepatitis B treatment involving Guangsheng Zhonglin, the innovative pharmaceutical subsidiary of the company, was approved; the phase III clinical trial of the innovative hepatitis B drug Nericovir GST-HG141 completed the enrollment of all 578 subjects; the issuance of A-shares to specific targets was completed, and the actual net capital raised was 710 million yuan.